{
    "nct_id": "NCT06486441",
    "official_title": "A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy",
    "inclusion_criteria": "* Documented evidence of recurrent/persistent endometrial cancer (endometrial carcinoma or carcinosarcoma).\n* Up to 3 prior lines of systemic therapy for endometrial cancer, including systemic platinum-based chemotherapy and anti-PD-1/PD-L1 therapy, either in combination or separately.\n* Eligible for treatment with either doxorubicin or paclitaxel as determined by the investigator.\n* Radiologically evaluable disease (either measurable or nonmeasurable) by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1.\n* Eastern Cooperative Oncology Group performance status score of 0 or 1.\n* Adequate organ function\n\nKey\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Uterine leiomyosarcoma and endometrial stromal sarcomas are excluded.\n* Participants who are candidates for curative-intent therapy at the time of study enrollment.\n* Participants eligible for rechallenge with platinum-based chemotherapy as determined by the investigator.\n* Received any prior treatment with a Trop-2-directed antibody-drug conjugate (ADC).\n* Have an active second malignancy.\n* Have an active serious infection requiring systemic antimicrobial therapy.\n* Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal perforation within 6 months prior to randomization.\n* Have a positive serum pregnancy test or are breastfeeding for participants who are assigned female at birth.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}